Evidence map›Paper›PMID 39576732›Full record

Trial reportClinical and translational science2024

Randomized evaluation of the loss-of-function carboxylesterase 1 (CES1) G143E variant on clopidogrel and ticagrelor pharmacodynamics.

Joshua P Lewis, Kathleen A Ryan, Elizabeth A Streeten, Hilary B Whitlatch, Melanie Daue, Keith Tanner, James A Perry, Jeffrey R O'Connell, Alan R Shuldiner, Braxton D Mitchell

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical and translational science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Increased Plasma Concentrations of 6-oxo-Methylphenidate inMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Joshua P LewisDivision of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-4107-6066
Kathleen A RyanDivision of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-1158-8455
Elizabeth A StreetenDivision of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-9771-6958
Hilary B WhitlatchDivision of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-5770-6544
Melanie DaueDivision of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-1353-5015
Keith TannerDivision of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
James A PerryDivision of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-5050-2074
Jeffrey R O'ConnellDivision of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Alan R ShuldinerDivision of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-9921-4305
Braxton D MitchellDivision of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-4920-4744

Funding

The Impact of Carboxylesterase 1 ( CES1 ) in Personalized Antiplalet TherapyR01HL137922 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI LEWIS, JOSHUA PATRICK · 2017 to 2021
$1.9M
NHLBI NIH HHS R01 HL137922NIH HHS R01HL137922
6 · The paper itself

Abstract

Antiplatelet therapy with a P2Y

Indexed as

Carboxylic Ester HydrolasesClopidogrelCross-Over StudiesPlatelet AggregationPlatelet Aggregation InhibitorsTicagrelorAdultAgedFemaleGenotypeHumansLoss of Function MutationMaleMiddle AgedMutation, MissenseProspective StudiesCarboxylic Ester HydrolasesCES1 protein, humanClopidogrelPlatelet Aggregation InhibitorsTicagrelor

Identifiers

PMID39576732
PMCPMC11583987

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.